Daniel D Billadeau Selected Research

Glycogen Synthase Kinases

1/2020	Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer.
11/2019	Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
3/2016	GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression.
4/2009	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
2/2006	Targeting GSK-3: a promising approach for cancer therapy?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel D Billadeau Research Topics

Disease

42	Neoplasms (Cancer) 04/2022 - 01/2002
31	Pancreatic Neoplasms (Pancreatic Cancer) 04/2022 - 01/2002
7	Inflammation (Inflammations) 01/2016 - 10/2003
6	Cicatrix (Scar) 01/2022 - 11/2009
5	Neoplasm Metastasis (Metastasis) 04/2022 - 01/2006
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 07/2014
2	Lymphoma (Lymphomas) 01/2019 - 02/2005
2	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 09/2005
2	Carcinogenesis 06/2014 - 01/2002
2	Adenocarcinoma 03/2014 - 09/2006
1	Chromosomal Instability (Chromosome Stability) 09/2022
1	Infections 01/2022
1	Starvation 01/2021
1	Protein Deficiency 01/2021
1	Melanoma (Melanoma, Malignant) 01/2020
1	Prader-Willi Syndrome (Syndrome, Prader-Willi) 01/2020
1	Pancreatic Diseases (Pancreatic Disease) 02/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019
1	Atherosclerosis 01/2018
1	Dyslipidemias (Dyslipidemia) 01/2018
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2018
1	Pancreatitis 01/2017
1	Metaplasia 01/2017
1	Breast Neoplasms (Breast Cancer) 10/2016
1	Pleural Effusion (Pleural Effusions) 10/2016
1	Intellectual Disability (Idiocy) 03/2016
1	Multiple Myeloma 01/2016
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2016
1	Parkinson Disease (Parkinson's Disease) 10/2015

Drug/Important Bio-Agent (IBA)

9	Glycogen Synthase (Synthase I)IBA 07/2021 - 03/2005
9	Glycogen Synthase Kinase 3IBA 11/2019 - 03/2005
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2002
6	Glycogen Synthase Kinase 3 betaIBA 04/2009 - 03/2005
6	NF-kappa B (NF-kB)IBA 07/2007 - 10/2003
5	Wiskott-Aldrich Syndrome ProteinIBA 01/2022 - 11/2009
5	Glycogen Synthase KinasesIBA 01/2020 - 02/2006
5	Transcription Factors (Transcription Factor)IBA 03/2016 - 10/2003
4	LigandsIBA 01/2020 - 05/2006
4	Phosphotransferases (Kinase)IBA 11/2019 - 03/2005
4	Small Interfering RNA (siRNA)IBA 11/2019 - 02/2005
4	Gemcitabine FDA Link 11/2019 - 11/2008
3	Messenger RNA (mRNA)IBA 01/2022 - 01/2019
3	Protein Isoforms (Isoforms)IBA 01/2020 - 06/2009
3	NFATC Transcription FactorsIBA 03/2016 - 02/2015
3	GTP Phosphohydrolases (GTPases)IBA 01/2014 - 05/2004
2	CytokinesIBA 04/2022 - 01/2014
2	Pharmaceutical PreparationsIBA 01/2022 - 10/2016
2	Epidermal Growth Factor (EGF)IBA 01/2021 - 01/2016
2	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2016
2	vasodilator-stimulated phosphoproteinIBA 01/2018 - 01/2015
2	ChromatinIBA 11/2017 - 11/2008
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 10/2016 - 01/2007
2	CyclinsIBA 03/2016 - 06/2014
2	Histone MethyltransferasesIBA 01/2016 - 11/2008
2	ErbB Receptors (EGF Receptor)IBA 05/2015 - 01/2005
2	Glucose (Dextrose)FDA LinkGeneric 02/2014 - 01/2008
2	Histone Deacetylase InhibitorsIBA 02/2010 - 03/2008
2	Biological ProductsIBA 04/2009 - 01/2006
2	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2009 - 01/2008
2	AcridinesIBA 01/2009 - 01/2008
2	Histone Deacetylases (Histone Deacetylase)IBA 06/2008 - 03/2008
2	beta CateninIBA 02/2006 - 09/2005
1	Hydroxyurea (Hydrea)FDA LinkGeneric 09/2022
1	ElementsIBA 01/2022
1	CalciumIBA 01/2022
1	CopperIBA 01/2021
1	CamptothecinIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	AntigensIBA 01/2020
1	RNA IsoformsIBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	Complementary DNA (cDNA)IBA 01/2020
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2020
1	NeuropeptidesIBA 01/2020
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2020
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020
1	GlypicansIBA 02/2019
1	Glycoproteins (Glycoprotein)IBA 02/2019
1	Biomarkers (Surrogate Marker)IBA 02/2019
1	Multiprotein ComplexesIBA 01/2019
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019
1	Microfilament Proteins (Actin Binding Proteins)IBA 01/2018
1	Lipoproteins (Lipoprotein)IBA 01/2018
1	oxidized low density lipoproteinIBA 01/2018
1	IntegrinsIBA 01/2018
1	Apolipoprotein E3IBA 01/2018
1	matrigelIBA 01/2018
1	EnzymesIBA 01/2017
1	Fructose-BisphosphataseIBA 01/2017
1	Irinotecan (Camptosar)FDA LinkGeneric 10/2016
1	LDL CholesterolIBA 03/2016
1	EuchromatinIBA 03/2016
1	SRT1460IBA 01/2016
1	SRT3025IBA 01/2016
1	SRT1720IBA 01/2016
1	Sirtuin 1IBA 01/2016
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 10/2015

Therapy/Procedure

11	Therapeutics 01/2022 - 02/2006
5	Drug Therapy (Chemotherapy) 07/2021 - 11/2008
1	Immunotherapy 01/2022